Isoxyl assays in plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 60, Issue , 2012, Pages 1-6

  Wang, Chenchen ^a,b   Garcia Contreras, Lucila ^a,c   Muttil, Pavan ^a,d   Hickey, Anthony J ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b ALLERGAN INC   (United States)

^c University of New Mexico ^*  (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Isoxyl; Metabolism; Method validation; Minimum inhibitory concentration; Tuberculosis

Indexed keywords

TIOCARLIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; GUINEA PIG; LIMIT OF DETECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 83955163670     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.10.029     Document Type: Article

References (19)

1. Eule H., Werner E. Thiocarlide (4'4-diisoamyloxythiocarbanilide) blood levels in patients suffering from tuberculosis. Tubercle 1966, 47:214-219.
2. Robinson O.P., Hunter P.A. Absorption and excretion studies with thiocarlide (4'4-diisoamyloxythiocarbanilide) in man. Tubercle 1966, 47:207-213.
3. Lambelin G. Pharmacology and toxicology of isoxyl. Antibiot. Chemother. 1970, 16:84-95.
4. Lambelin G., Roncucci R., Simon M.J., Gautier M., Vincze A., Verbist L. Simultaneous determination of double labelled isoxyl (3H and 35S) blood levels in man, by radio- and bio-assays. Beitr. Klin. Erforsch. Tuberk. Lungenkr. 1968, 138:161-172.
5. Freerksen E. Blood-level determinations after administration of isoxyl by microbiological methods and with radioactive labeled (35S) isoxyl in rabbits and humans. Trans. 24th Res. Conf. Pulm. Dis. 1965.
6. Emerson P.A., Nicholson J.P. The absorption of 4-4-diisoamyloxythiocarbanilide (isoxyl) using radioactive material (S.35 tagged), Veterans Administration-Armed Forces. Trans. 24th Res. Conf. Pulm. Dis. 1965.
7. Dover L.G., Alahari A., Gratraud P., Gomes J.M., Bhowruth V., Reynolds R.C., Besra G.S., Kremer L. EthA a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob. Agents Chemother. 2007, 51:1055-1063.
8. Kordulakova J., Janin Y.L., Liav A., Barilone N., Dos Vultos T., Rauzier J., Brennan P.J., Gicquel B., Jackson M. Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2007, 51:3824-3829.
9. Gupta U.D., Katoch V.M. Animal models of tuberculosis for vaccine development. Indian J. Med. Res. 2009, 129:11-18.
10. Crowle A.J., Mitchell R.S., Petty T.L. The effectiveness of a thiocarbanilide (isoxyl) as a therapeutic drug in mouse tuberculosis. Am. Rev. Respir. Dis. 1963, 88:716-717.
11. Freerksen E. Experiences with isoxyl in experimental therapy. Trans. 23th Res. Conf. Pulm. Dis. 1964.
12. Rosenfeld M. Rifampicin, myambutol, isoxyl, and capreomycin as combination partners in animal experiments. Antibiot. Chemother. 1970, 16:501-515.
13. Stahle I. Monotherapy with 4-4'-diisoamyloxythio-carbanilide (isoxyl). Acta Tuberc. Pneumol. Scand. 1964, 44:327-334.
14. Antituberculosis Drugs 1988, 185-189. Springer-Verlag. G.V.R. Born (Ed.).
15. Mitchell R.S., Petty T.L., Dye W.E. Clinical and pharmacological studies of isoxyl. Trans. 23th Res. Conf. Pulm. Dis. 1964.
16. Meissner G., Meissner J. Absorption and distribution of [3H]- and [35S]-4,4'-di(isoamyloxy)thiocarbanilide (thiocarlide) in rabbits. Nuklearmedizin. Supplementum. 1970, 8:177-182.
17. Urbancik R., Trnka L. Report on the antimicrobial activity of isoxyl on M. tuberculosis "in vitro" and "in vio" Acta Tuberc. Pneumol. Belg. 1963, 54:66-86.
18. Isoxyl. Tubercle 1965, 46:298-300.
19. Tousek J. On the clinical effectiveness of isoxyl. Antibiot. Chemother. 1970, 16:149-155.